Immunotherapy for LELC: Case Report and a Focused Review

Area of Science:

• Oncology
• Virology
• Pathology

Background:

• Lymphoepithelioma-like carcinoma of the lung (LELC) is a rare malignancy associated with Epstein-Barr virus.
• It predominantly affects young, Asian, non-smoking individuals.
• Optimal treatment strategies for LELC remain undefined, with surgery for early stages and cisplatin-based chemotherapy for metastatic disease.

Observation:

• Despite a potentially better prognosis than other non-small-cell lung cancers, advanced LELC has a poor prognosis with a median survival of 24 months.
• Immunotherapies, particularly programmed cell death 1 (PD-1) inhibitors, are increasingly vital in non-small-cell lung cancer treatment.
• Limited data exist on immunotherapy efficacy in the rare LELC subgroup.

Findings:

• This review focuses on initial cases of LELC demonstrating a positive response to programmed cell death 1 (PD-1) inhibitor therapy.
• Preliminary findings suggest that PD-1 inhibitors may offer a viable treatment option for LELC.

Implications:

• The findings highlight the potential of programmed cell death 1 (PD-1) inhibitors as a novel therapeutic avenue for lymphoepithelioma-like carcinoma of the lung.
• Further research is warranted to establish the role and efficacy of immunotherapies in managing this rare lung cancer subtype.
• These advancements could lead to improved outcomes for patients with advanced LELC, addressing a critical unmet need.